Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

[en] The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex. Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic agents for T2DM. By targeting the kidney, they have a unique mechanism of action, which results in enhanced glucosuria, osmotic diuresis and natriuresis, thereby improving glucose control with a limited risk of hypoglycaemia and exerting additional positive effects such as weight loss and the lowering of blood pressure. Several outcome studies with canagliflozin, dapagliflozin or empagliflozin reported a statistically significant reduction in major cardiovascular events, hospitalization for heart failure and progression to advanced renal disease in patients with T2DM who have established atherosclerotic cardiovascular disease, several cardiovascular risk factors, albuminuric mild to moderate chronic kidney disease or heart failure. Current guidelines proposed a new paradigm in the management of T2DM, with a preferential place for SGLT2is, after metformin, in patients with atherosclerotic cardiovascular disease, heart failure and progressive kidney disease. Ongoing trials might extend the therapeutic potential of SGLT2is in patients with, but also without, T2DM. This Review provides an update of the current knowledge on SGLT2is, moving from their use as glucose-lowering medications to their new positioning as cardiovascular and renal protective agents.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Publication date :

2020

Journal title :

Nature Reviews. Endocrinology

ISSN :

1759-5029

eISSN :

1759-5037

Publisher :

Nature Publishing Group, United Kingdom

Volume :

Pages :

556-577

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 December 2020

Statistics

Number of views

73 (1 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

179

Scopus citations^®
without self-citations

131

OpenCitations

107

Bibliography

Tancredi, M. et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015).
Bommer, C. et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 5, 423–430 (2017).
Scheen, A. J. & Charbonnel, B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab. 40, 176–185 (2014).
Kirkman, M. S., Mahmud, H. & Korytkowski, M. T. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus. Endocrinol. Metab. Clin. North. Am. 47, 81–96 (2018).
Lipska, K. J. et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care 40, 468–475 (2017).
Ryden, L. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 34, 3035–3087 (2013).
Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).
Fattah, H. & Vallon, V. The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. Drugs 78, 717–726 (2018).
Pereira, M. J. & Eriksson, J. W. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 79, 219–230 (2019).
Inzucchi, S. E. et al. Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care 42, e53–e55 (2019).
Ferrannini, E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 27–38 (2017).
Brown, E., Rajeev, S. P., Cuthbertson, D. J. & Wilding, J. P. H. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes. Metab. 21, 9–18 (2019).
DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).
Trujillo, J. M. & Nuffer, W. A. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy 37, 481–491 (2017).
Chilton, R. J. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes Obes. Metab. 22, 16–29 (2020).
Abdul-Ghani, M. A., Norton, L. & Defronzo, R. A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr. Rev. 32, 515–531 (2011).
Scheen, A. J. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75, 33–59 (2015).
Scheen, A. J. & Paquot, N. Metabolic effects of SGLT2 inhibitors beyond increased glucosuria: a review of clinical evidence. Diabetes Metab. 40, S4–S11 (2014).
DeFronzo, R. A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773–795 (2009).
Yki-Jarvinen, H. Glucose toxicity. Endocr. Rev. 13, 415–431 (1992).
Kaneto, H. et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance. J. Diabetes 9, 219–225 (2017).
Merovci, A. et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J. Clin. Endocrinol. Metab. 100, 1927–1932 (2015).
Al Jobori, H. et al. Empagliflozin treatment is associated with improved β-cell function in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 1402–1407 (2018).
Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).
Pedersen, M. G., Ahlstedt, I., El Hachmane, M. F. & Gopel, S. O. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci. Rep. 6, 31214 (2016).
Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509–514 (2014).
Goldenberg, R. M., Verma, S., Perkins, B. A., Gilbert, J. D. & Zinman, B. Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the Yin and Yang of glucagon? Can. J. Diabetes 41, 6–9 (2017).
Imprialos, K. et al. SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus: a comprehensive and critical review of the literature. Curr. Pharm. Des. 23, 1510–1521 (2017).
Vallon, V. & Thomson, S. C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60, 215–225 (2017).
Lee, P. C., Ganguly, S. & Goh, S. Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes. Rev. 19, 1630–1641 (2018).
Bolinder, J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97, 1020–1031 (2012).
Schork, A. et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc. Diabetol. 18, 46 (2019).
Cai, X. et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. J. Diabetes Investig. 8, 510–517 (2017).
Ferrannini, E. et al. Shift to fatty substrates utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190–1195 (2016).
Wang, Y., Hu, X., Liu, X. & Wang, Z. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther. Clin. Risk Manag. 12, 1113–1131 (2016).
Bays, H. E., Sartipy, P., Xu, J., Sjostrom, C. D. & Underberg, J. A. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J. Clin. Lipidol. 11, 450–458 (2017).
Zaccardi, F. et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes. Metab. 18, 783–794 (2016).
Fadini, G. P. et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc. Diabetol. 16, 42 (2017).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Zhao, Y. et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 20, 458–462 (2018).
Ahmadieh, H. & Azar, S. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus. Diabetes Technol. Ther. 19, 507–512 (2017).
Xu, L. & Ota, T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte 7, 121–128 (2018).
Garvey, T. W. et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 85, 32–37 (2018).
Bonnet, F. & Scheen, A. J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab. 44, 457–464 (2018).
Heerspink, H. J. L. et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62, 1154–1166 (2019).
Prattichizzo, F., De Nigris, V., Micheloni, S., La Sala, L. & Ceriello, A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? Diabetes Obes. Metab. 20, 2515–2522 (2018).
List, J. F., Woo, V., Morales, E., Tang, W. & Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32, 650–657 (2009).
Yasui, A. et al. Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes. Diabetes Ther. 9, 863–871 (2018).
Blau, J. E. et al. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3, 99123 (2018).
Tanaka, H. et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv. Ther. 34, 436–451 (2017).
Eickhoff, M. K. et al. Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J. Clin. Med. 8, 779 (2019).
Ansary, T. M., Nakano, D. & Nishiyama, A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int. J. Mol. Sci. 20, 629 (2019).
Sha, S. et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 16, 1087–1095 (2014).
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B. & List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15, 853–862 (2013).
Dekkers, C. C. J. et al. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes. Metab. 21, 2667–2673 (2019).
Ohara, K. et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan. Nephrology 24, 904–911 (2018).
Oliva, R. V. & Bakris, G. L. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 8, 330–339 (2014).
Maliha, G. & Townsend, R. R. SGLT2 inhibitors: their potential reduction in blood pressure. J. Am. Soc. Hypertens. 9, 48–53 (2015).
Imprialos, K. P., Sarafidis, P. A. & Karagiannis, A. I. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J. Hypertens. 33, 2185–2197 (2015).
Sternlicht, H. & Bakris, G. L. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. Curr. Hypertens. Rep. 21, 12 (2019).
Scheen, A. J. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr. Cardiol. Rep. 21, 70 (2019).
Baker, W. L. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J. Am. Soc. Hypertens. 8, 262–275 (2014).
Mazidi, M., Rezaie, P., Gao, H. K. & Kengne, A. P. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J. Am. Heart Assoc. 6, e004007 (2017).
Baker, W. L. et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J. Am. Heart Assoc. 6, e005686 (2017).
Sano, M. & Goto, S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139, 1985–1987 (2019).
Tang, H. et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59, 2546–2551 (2016).
Toto, R. D. et al. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. J. Diabetes Complications 33, 107402 (2019).
Weir, M. R., Kline, I., Xie, J., Edwards, R. & Usiskin, K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr. Med. Res. Opin. 30, 1759–1768 (2014).
Vinke, J. S. J., Heerspink, H. J. L. & de Borst, M. H. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Curr. Opin. Nephrol. Hypertens. 28, 321–327 (2019).
Filippatos, T. D., Tsimihodimos, V., Liamis, G. & Elisaf, M. S. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab. Syndr. 12, 59–63 (2018).
Scheen, A. J. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin. Pharmacokinet. 54, 691–708 (2015).
van Baar, M. J. B. et al. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41, 1543–1556 (2018).
Shyangdan, D. S., Uthman, O. A. & Waugh, N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6, e009417 (2016).
Feng, M. et al. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine 98, e16575 (2019).
Wang, Z. et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes. Metab. 20, 113–120 (2018).
Jingfan, Z., Ling, L., Cong, L., Ping, L. & Yu, C. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis. Arch. Endocrinol. Metab. 63, 478–486 (2019).
Zhang, Q., Dou, J. & Lu, J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res. Clin. Pract. 105, 313–321 (2014).
Scheen, A. J. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. Diabetes Metab. 46, 186–196 (2020).
Milder, T. Y. et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis. J. Clin. Med. 8, 45 (2019).
Li, J. et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocr. J. 65, 335–344 (2018).
Scheen, A. J. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin. Drug Metab. Toxicol. 12, 1407–1417 (2016).
Dey, J. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. Postgrad. Med. 129, 409–420 (2017).
Li, D., Shi, W., Wang, T. & Tang, H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 20, 1972–1976 (2018).
Liao, H. W., Wu, Y. L., Sue, Y. M., Lee, M. & Ovbiagele, B. Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Endocrinol. Diabetes Metab. 2, e00050 (2019).
Fulcher, G. et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 18, 82–91 (2016).
Ludvik, B. et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 370–381 (2018).
Frias, J. P. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 4, 1004–1016 (2016).
Jabbour, S. A. et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care 41, 2136–2146 (2018).
Tang, H. et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 19, 142–147 (2017).
Lee, J. Y. et al. Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes. Diabetes Metab. 43, 191–194 (2017).
Bujac, S. et al. Patient characteristics are not associated with clinically important differential response to dapagliflozin: a staged analysis of phase 3 data. Diabetes Ther. 5, 471–482 (2014).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
Cai, X. et al. No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. J. Diabetes Investig. 9, 850–861 (2018).
Fujita, Y. & Inagaki, N. An update on efficacy and safety of SGLT2 inhibitors in Asians and non-Asians. J. Diabetes Investig. 10, 1408–1410 (2019).
Scheen, A. J. Pharmacokinetic/pharmacodynamic properties and clinical use of SGLT2 inhibitors in non-Asian and Asian patients with type 2 diabetes and chronic kidney disease. Clin. Pharmacokinet. 10.1007/s40262-020-00885-z (2020).
Lim, L. L., Tan, A. T., Moses, K., Rajadhyaksha, V. & Chan, S. P. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. J. Diabetes Complications 31, 494–503 (2017).
Davidson, J. A. et al. Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity. Ethn. Dis. 26, 221–228 (2016).
Ferdinand, K. C. et al. Antihyperglycemic and blood pressure effects of empagliflozin in Black patients with type 2 diabetes mellitus and hypertension. Circulation 139, 2098–2109 (2019).
Cintra, R. et al. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Rev. Assoc. Med. Bras. 65, 70–86 (2019).
Kambara, T. et al. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatr. Gerontol. Int. 18, 108–114 (2018).
Mikhail, N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South. Med. J. 108, 91–96 (2015).
Kohan, D. E., Fioretto, P., Tang, W. & List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85, 962–971 (2014).
Delanaye, P. & Scheen, A. J. Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin. Pharmacother. 20, 277–294 (2019).
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E. & Cherney, D. Z. I. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 94, 26–39 (2018).
Kelly, M. S., Lewis, J., Huntsberry, A. M., Dea, L. & Portillo, I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad. Med. 131, 31–42 (2019).
Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31–39 (2019).
Davidson, J. A. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad. Med. 131, 251–260 (2019).
Food and Drug Administration: Center for Drug Evaluation and Research. Canagliflozin (Invokana): summary review (Application number: 204042Orig1s000). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000SumR.pdf (2020).
Tang, H. et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am. J. Cardiol. 118, 1774–1780 (2016).
Sonesson, C., Johansson, P. A., Johnsson, E. & Gause-Nilsson, I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc. Diabetol. 15, 37 (2016).
Salsali, A., Kim, G., Woerle, H. J., Broedl, U. C. & Hantel, S. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes. Metab. 18, 1034–1040 (2016).
Savarese, G. et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int. J. Cardiol. 220, 595–601 (2016).
Cefalu, W. T. et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 41, 14–31 (2018).
Hupfeld, C. & Mudaliar, S. Navigating the “MACE” in cardiovascular outcomes trials and decoding the relevance of atherosclerotic CVD benefits versus heart failure benefits. Diabetes Obes. Metab. 21, 1780–1789 (2019).
Cannon, C. P. et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am. Heart J. 206, 11–23 (2018).
Furtado, R. H. M. et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139, 2516–2527 (2019).
Kaul, S. Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true? Circulation 134, 94–96 (2016).
Fitchett, D. et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J. Am. Coll. Cardiol. 71, 364–367 (2018).
Claggett, B. et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation 138, 1599–1601 (2018).
Fitchett, D. et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular rRisk in the EMPA-REG OUTCOME trial. Circulation 139, 1384–1395 (2019).
Wanner, C. et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137, 119–129 (2018).
Cosentino, F., Grant, P. J., Aboyans, V. & ESC Scientific Document Group et al. 2019 ESC guidelines on diabetes, prediabetes and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255–323 (2020).
Kato, E. T. et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139, 2528–2536 (2019).
Sinha, B. & Ghosal, S. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events: a meta-analysis. Diabetes Ther. 10, 891–899 (2019).
Zinman, B. et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 48, 1218–1225 (2017).
Zhou, Z. et al. Canagliflozin and stroke in type 2 diabetes mellitus. Stroke 50, 396–404 (2019).
Guo, M. et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes. Metab. 20, 1977–1982 (2018).
Fitchett, D. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur. Heart J. 37, 1526–1534 (2016).
Januzzi, J. et al. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur. J. Heart Fail. 21, 386–388 (2019).
Fitchett, D. et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur. Heart J. 39, 363–370 (2018).
Savarese, G. et al. Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality. Circulation 139, 1458–1460 (2019).
Radholm, K. et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138, 458–468 (2018).
Mahaffey, K. W. et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140, 739–750 (2019).
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D. & McMurray, J. J. SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59, 1333–1339 (2016).
Martinez, F. A. et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 141, 100–111 (2020).
Scheen, A. J. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab. 45, 110–121 (2019).
Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 7, 845–854 (2019).
Seidu, S. et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Prim. Care Diabetes 12, 265–283 (2018).
Toyama, T. et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes. Metab. 21, 1237–1250 (2019).
Giugliano, D., De Nicola, L., Maiorino, M. I., Bellastella, G. & Esposito, K. Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. Diabetes Obes. Metab. 21, 1790–1800 (2019).
Wanner, C. et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J. Am. Soc. Nephrol. 29, 2755–2769 (2018).
Cherney, D. Z. I. et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5, 610–621 (2017).
Mahaffey, K. W. et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137, 323–334 (2018).
Neuen, B. L. et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation 138, 1537–1550 (2018).
Neuen, B. L. et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J. Am. Soc. Nephrol. 30, 2229–2242 (2019).
Mosenzon, O. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 7, 606–617 (2019).
Staels, B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am. J. Cardiol. 120, S28–S36 (2017).
Vettor, R., Inzucchi, S. E. & Fioretto, P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia 60, 395–398 (2017).
Chin, K. L. et al. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc. Res. 115, 266–276 (2019).
Scheen, A. J. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab. 42, 71–76 (2016).
Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134, 752–772 (2016).
Inzucchi, S. E. et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 138, 1904–1907 (2018).
Cooper, M. E. et al. Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial. Am. J. Kidney Dis. 74, 713–715 (2019).
Heerspink, H. J. et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J. Am. Soc. Nephrol. 28, 368–375 (2017).
Budoff, M. J. & Wilding, J. P. H. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Int. J. Clin. Pract. 71, e12948 (2017).
Deeks, E. D. & Scheen, A. J. Canagliflozin: a review in type 2 diabetes. Drugs 77, 1577–1592 (2017).
Petrykiv, S. et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin. J. Am. Soc. Nephrol. 12, 751–759 (2017).
Inzucchi, S. E. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41, 356–363 (2018).
Scheen, A. J. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res. Clin. Pract. 121, 204–214 (2016).
Scheen, A. J. & Delanaye, P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 43, 99–109 (2017).
Yaribeygi, H., Atkin, S. L., Butler, A. E. & Sahebkar, A. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J. Cell Physiol. 234, 3231–3237 (2019).
Pulakazhi Venu, V. K. et al. Minimizing hyperglycemia-induced vascular endothelial dysfunction by inhibiting endothelial sodium-glucose cotransporter 2 and attenuating oxidative stress: implications for treating individuals with type 2 diabetes. Can. J. Diabetes 43, 510–514 (2019).
Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39, 1108–1114 (2016).
Mudaliar, S., Alloju, S. & Henry, R. R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39, 1115–1122 (2016).
Qiu, H., Novikov, A. & Vallon, V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab. Res. Rev. 10.1002/dmrr.2886 (2017).
Bailey, C. J. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes. Metab. 21, 1291–1298 (2019).
Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A. & Cherney, D. Z. I. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136, 1643–1658 (2017).
Muskiet, M. H., van Raalte, D. H., van Bommel, E., Smits, M. M. & Tonneijck, L. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 3, 928–929 (2015).
Fioretto, P., Zambon, A., Rossato, M., Busetto, L. & Vettor, R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39, S165–S171 (2016).
Alicic, R. Z., Neumiller, J. J., Johnson, E. J., Dieter, B. & Tuttle, K. R. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes 68, 248–257 (2019).
Yaribeygi, H., Butler, A. E., Atkin, S. L., Katsiki, N. & Sahebkar, A. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J. Cell Physiol. 234, 223–230 (2018).
Kuriyama, S. A potential mechanism of cardio-renal protection with sodium-glucose cotransporter 2 inhibitors: amelioration of renal congestion. Kidney Blood Press. Res. 44, 449–456 (2019).
Nespoux, J. & Vallon, V. Renal effects of SGLT2 inhibitors: an update. Curr. Opin. Nephrol. Hypertens. 29, 190–198 (2020).
Packer, M., Anker, S. D., Butler, J., Filippatos, G. & Zannad, F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2, 1025–1029 (2017).
McCullough, P. A. et al. Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2. Rev. Cardiovasc. Med. 19, 51–63 (2018).
Qiu, R. et al. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr. Med. Res. Opin. 33, 553–562 (2017).
Jabbour, S. et al. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes. Metab. 20, 620–628 (2018).
Kohler, S., Zeller, C., Iliev, H. & Kaspers, S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv. Ther. 34, 1707–1726 (2017).
Zhang, X. L. et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J. Am. Heart Assoc. 7, e007165 (2018).
Fitchett, D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes. Metab. 21, 34–42 (2019).
Scheen, A. J. An update on the safety of SGLT2 inhibitors. Expert Opin. Drug Saf. 18, 295–311 (2019).
Donnan, J. R. et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open 9, e022577 (2019).
Scheen, A. J. SGLT2 inhibitors: benefit/risk balance. Curr. Diab. Rep. 16, 92 (2016).
Lupsa, B. C. & Inzucchi, S. E. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 61, 2118–2125 (2018).
Vallon, V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 66, 255–270 (2015).
Vasilakou, D. et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 159, 262–274 (2013).
Puckrin, R. et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55, 503–514 (2018).
Dave, C. V. et al. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann. Intern. Med. 171, 248–256 (2019).
Wu, J. H. et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 4, 411–419 (2016).
Yang, X. P., Lai, D., Zhong, X. Y., Shen, H. P. & Huang, Y. L. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 70, 1149–1158 (2014).
Liakos, A. et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 16, 984–993 (2014).
Sjostrom, C. D., Johansson, P., Ptaszynska, A., List, J. & Johnsson, E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc. Dis. Res. 12, 352–358 (2015).
Peters, A. L. et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38, 1687–1693 (2015).
Taylor, S. I., Blau, J. E. & Rother, K. I. SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849–2852 (2015).
Rosenstock, J. & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015).
Bonora, B. M., Avogaro, A. & Fadini, G. P. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes. Metab. 20, 25–33 (2018).
Monami, M., Nreu, B., Zannoni, S., Lualdi, C. & Mannucci, E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res. Clin. Pract. 130, 53–60 (2017).
Fralick, M., Schneeweiss, S. & Patorno, E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N. Engl. J. Med. 376, 2300–2302 (2017).
Wang, L. et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiol. Drug Saf. 28, 1620–1628 (2019).
Fadini, G. P., Bonora, B. M. & Avogaro, A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60, 1385–1389 (2017).
Blau, J. E., Tella, S. H., Taylor, S. I. & Rother, K. I. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab. Res. Rev. 10.1002/dmrr.2924 (2017).
Ado Moumouni, A. N., Robin, P., Hillaire-Buys, D. & Faillie, J. L. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database. Fundam. Clin. Pharmacol. 32, 216–226 (2018).
Taylor, S. I., Blau, J. E. & Rother, K. I. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 3, 8–10 (2015).
de Jong, M. A. et al. Effects of dapagliflozin on circulating markers of phosphate homeostasis. Clin. J. Am. Soc. Nephrol. 14, 66–73 (2019).
Blau, J. E. & Taylor, S. I. Adverse effects of SGLT2 inhibitors on bone health. Nat. Rev. Nephrol. 14, 473–474 (2018).
Mannucci, E. & Monami, M. Bone fractures with sodium-glucose co-transporter-2 inhibitors: how real is the risk? Drug Saf. 40, 115–119 (2017).
Zhou, Z. et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia 62, 1854–1867 (2019).
Patel, S., Gohel, K. & Patel, B. G. A systematic review on effect of canagliflozin in special population. Curr. Diabetes Rev. 12, 211–222 (2016).
Blevins, T. C. & Farooki, A. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgrad. Med. 129, 159–168 (2017).
Matthews, D. R. et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia 62, 926–938 (2019).
U.S. Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf (2017).
Inzucchi, S. E., Iliev, H., Pfarr, E. & Zinman, B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41, e4–e5 (2018).
Verma, S. et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137, 405–407 (2018).
Scheen, A. J. Does lower-limb amputation concern all SGLT-2 inhibitors? Nat. Rev. Endocrinol. 14, 326–328 (2018).
Tanaka, A. & Node, K. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovasc. Diabetol. 16, 129 (2017).
Szalat, A. et al. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 41, 239–252 (2018).
Briasoulis, A., Al Dhaybi, O. & Bakris, G. L. SGLT2 inhibitors and mechanisms of hypertension. Curr. Cardiol. Rep. 20, 1 (2018).
Tang, H. et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 19, 1106–1115 (2017).
Gilbert, R. E. & Thorpe, K. E. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes. Metab. 21, 1996–2000 (2019).
Ueda, P. et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363, k4365 (2018).
Nadkarni, G. N. et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40, 1479–1485 (2017).
Cahn, A., Melzer-Cohen, C., Pollack, R., Chodick, G. & Shalev, V. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes. Metab. 21, 340–348 (2019).
Chu, C., Lu, Y. P., Yin, L. & Hocher, B. The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press. Res. 44, 149–157 (2019).
Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm (2018).
Bersoff-Matcha, S. J., Chamberlain, C., Cao, C., Kortepeter, C. & Chong, W. H. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann. Intern. Med. 170, 764–769 (2019).
Fadini, G. P., Sarangdhar, M., De Ponti, F., Avogaro, A. & Raschi, E. Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res. Care 7, e000725 (2019).
Ismail-Beigi, F., Moghissi, E., Kosiborod, M. & Inzucchi, S. E. Shifting paradigms in the medical management of type 2 diabetes: reflections on recent cardiovascular outcome trials. J. Gen. Intern. Med. 32, 1044–1051 (2017).
Scheen, A. J. Series: implications of the recent CVOTs in type 2 diabetes: impact on guidelines: the endocrinologist point of view. Diabetes Res. Clin. Pract. 159, 107726 (2020).
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669–2701 (2018).
Buse, J. B. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 221–228 (2020).
Scheen, A. J. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ. Res. 122, 1439–1459 (2018).
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 74, 1376–1414 (2019).
Scheen, A. J. Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes Metab. 46, 181–185 (2020).
Zelniker, T. A. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139, 2022–2031 (2019).
Kosiborod, M. et al. Lower risk of heart failure and death in patients initiated on Sodium-Glucose Cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136, 249–259 (2017).
Kosiborod, M. et al. Lower cardiovascular risk associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J. Am. Coll. Cardiol. 71, 2628–2639 (2018).
Norhammar, A. et al. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes Obes. Metab. 21, 1136–1145 (2019).
Gallwitz, B. The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors - Real-world data. Eur. Endocrinol. 14, 17–23 (2018).
Raschi, E., Poluzzi, E., Fadini, G. P., Marchesini, G. & De Ponti, F. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes. Metab. 20, 2711–2723 (2018).
Suissa, S. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 41, 6–10 (2018).
Scheen, A. J. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res. Clin. Pract. 143, 88–100 (2018).
Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21, 968–974 (2019).
Herrington, W. G. et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin. Kidney J. 11, 749–761 (2018).
Butler, J. et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur. J. Heart Fail. 19, 1390–1400 (2017).
Nassif, M. E. & Kosiborod, M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes. Metab. 21, 19–23 (2019).
Seferovic, P. M. et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 20, 853–872 (2018).
Wanner, C. & Marx, N. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61, 2134–2139 (2018).
Scheen, A. J. Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin? Diabetes Res. Clin. Pract. 147, 169–171 (2019).
Kuo, S., Ye, W., Duong, J. & Herman, W. H. Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. Diabetes Res. Clin. Pract. 141, 181–189 (2018).
Cannon, C. P. et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation 141, 407–410 (2020).